# Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

> **NCT03526432** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Oklahoma** · enrollment: 110 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03526432
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-08
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-09
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03526432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03526432, "Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03526432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*